Journal Logo



Nagler, A.1, 2; Labopin, M.3; Ruggeri, A.4; Ciceri, F.5; Sanz, J.6; Angelucci, E.7; Koc, Y.8; Gülbas, Z.9; Arcese, W.10; Tischer, J.11; Pioltelli, P.12; Ozdogu, H.13; Afanasyev, B.14; Wu, D.15; Arat, M.16; Peric, Z.17; Giebel, S.18; Mohty, M.19

doi: 10.1097/01.HS9.0000558676.16205.74
Simultaneous Sessions I: Alternative donor transplantation

1EBMT ALWP office, Saint Antoine Hospital, Paris, France

2Hematology Division, Chaim Sheba Medical Center, Tel Aviv University, Tel-Hashomer, Jersey

3Department of Haematology and EBMT Paris study office / CEREST-TC, Saint Antoine Hospital, Paris, France

4Department of Pediatric Hematology and Oncology IRCCS, Ospedale Pediatrico Bambino Gesù, Roma

5Ospedale San Raffaele s.r.l., Milano, Italy

6Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia, CIBERONC, Instituto Carlos III, Madrid, Spain

7Hematology and transplant center, IRCCS Ospedale Policlinico San Martino, Genova, Italy

8Stem Cell Transplant Unit, Medical Park Hospitals, Antalya

9Bone Marrow Transplantation Department, Anadolu Medical Center Hospital, Kocaeli, Turkey

10Stem Cell Transplant Unit, ‘Tor Vergata’ University of Rome, Rome, Italy

11Med. Klinik III, Klinikum Grosshadern, Munich, Germany

12Clinica Ematologica dell‘Universita Milano-Biocca, Ospedale San Gerardo, Monza, Italy

13Haematology Division, BMT Unit, Baskent University Hospital, Adana, Turkey

14Raisa Gorbacheva Memorial Research Institute for Paediatric Oncology, Hematology, and Transplantation, First State Pavlov Medical University of St. Petersburg, St._Petersburg, Russian Federation

15Department of Hematology, First Affiliated Hospital of Soochow University, Suzhou, China

16Hematopoietic SCT Unit, Florence Nightingale Sisli Hospital, Istanbul, Turkey

17Department of Internal Medicine, University of Zagreb, School of Medicine, Zagreb, Croatia

18Department of Bone Marrow Transplantation and Oncohematology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland

19Department of Haematology and EBMT Paris study office / CEREST-TC, Saint Antoine Hospital, INSERM UMR 938 and Université Pierre et Marie Curie, Paris, France

Back to Top | Article Outline


The two leading strategies for Graft-versus-Host Disease (GvHD) prophylaxis in the setting of non-T-cell-depleted (T-replete) haploidentical stem cell transplantation (HaploSCT) are post-transplant cyclophosphamide (PTCy) and anti-thymocyte globulin (ATG). We have previously compared outcomes between these two approaches in patients undergoing HaploSCT for acute myelogenous leukemia (AML) in the registry of the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT; Ruggeri A, Hematologica, 2017), however results may differ in patients treated for acute lymphoblastic leukemia (ALL).

Back to Top | Article Outline


To compare PTCy with ATG-based GvHD prophylaxis in patients undergoing HaploSCT for ALL.

Back to Top | Article Outline


We analyzed all adult patients (≥ 18 years) reported to the EBMT with ALL in first or second complete remission (CR) or advanced disease at time of transplantation who underwent HaploSCT between 2007-2017 as first allogeneic transplantation. Haplo was defined as related donor with > 2 mismatched HLA alleles. Outcomes were compared using multivariable Cox regression analysis (MVA).

Back to Top | Article Outline


A total of 434 ALL patients were included; 336 received PTCy-based regimen and 98 received ATG. Median follow-up was 24 months (interquartile range 12-40). Median age was 35.6 (range 18-76) years, and 63% of patients were male. B-ALL predominated (69%), with 32% of patients Philadelphia (Ph)-negative, 36% were Ph+ while 32% had T ALL. The majority of patients (48%) was in first CR, with 20% of patients in advanced disease. Karnofsky performance status ≥ 90 was observed in 72% of patients. 53% of patients received peripheral blood (PB) grafts while 47% BM graft, and 75% of patients were treated with myeloablative conditioning while 25% reduced intensity conditioning. Patients who received ATG were treated earlier than those who received PTCy, with median year of transplantation 2011 and 2015, respectively (p < 0.0001), and were more likely to have advanced disease (31% vs 16%, p = 0.01). Patients treated with PTCy were more likely to have received PB grafts (68% vs 48% ATG, p < 0.001) and TBI-based conditioning (45% vs 26%, p < 0.001).

Similar outcomes were seen for engraftment (92.7% ATG vs 93.54% PTCy), as for 100 day incidence of acute GVHD both > Gr II and severe (Gr. II+, 32.7% vs 30.5%; Gr. III+, 11.6% vs 14.1%), and chronic GvHD (27.7% vs 31.7%). In both groups, infection accounted for 32% and 30% of deaths. In MVA, relapse incidence was lower in PTCy vs ATG: 2 year RI: 33.8% vs 43%; hazard ratio [HR] 0.61 [95% CI: 0.39-0.94], p = 0.03), with a trend toward lower non-relapse mortality (NRM) as well (26.7% vs 32.9%; HR 0.68 [0.42-1.11], p = 0.12). Both 2 year leukemia-free (LFS) and overall survival (OS) were higher for PTCY when compared with ATG (40.3% vs 24.1%; HR 0.67 [0.46-0.96], p = 0.03, and 48.4% vs 27.4%; HR 0.60 [0.42-0.84], p = 0.003, respectively) (Fig). Active disease and lower KPS were associated with lower LFS, OS and GRFS, while PB grafts were associated with higher incidence of both acute and chronic GvHD.



Back to Top | Article Outline


Among ALL patients receiving T-replete HaploSCT, GvHD prophylaxis with PTCy resulted in significantly lower RI and superior LFS and OS compared to ATG. These results are similar to previous observations in HaploSCT for AML.

Copyright © 2019 The Authors. Published by Wolters Kluwer Health Inc., on behalf of the European Hematology Association.